TY - JOUR
T1 - Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer
AU - Gualberto, Antonio
AU - Karp, Daniel D.
N1 - Funding Information:
This research was funded by Pfizer Inc. The authors thank the patients who participated in figitumumab studies and their families. We are also indebted to S. Green, D. Yin, W. Donaldson, J. Ferrara, L. Paccagnella, C. Melvin, P. Mensah, L. Bendle, P. Rowlands, K. Magnuson, K. Ferrante, A. Olszanski, M. Carpentieri, J. Scranton, B. Cohen, M. Lacy, P. Haluska, M. Pollak, J. de Bono, L.G. Paz-Ares, S. Novello, L. Garland, F. Cardenal, L.J. Blakely, P.D. Eisenberg, C.J. Langer, A.V. Lee, R. Herbst, A.A. Adjei, G. Scagliotti, and many others for their contributions to the development of figitumumab.
PY - 2009
Y1 - 2009
N2 - Figitumumab (CP-751,871) is a fully human immunoglobulin G2 monoclonal antibody highly potent and specific against the insulin-like growth factor-1 receptor. Figitumumab has an effective half-life of approximately 20 days, and it has been well tolerated in clinical studies when given alone or in combination with chemotherapy and targeted agents. Mild to moderate asymptomatic hyperglycemia is observed with figitumumab therapy, but it is generally manageable and well tolerated. Because of its extended half-life and absence of dose-limiting toxicity and hypersensitivity, figitumumab compares well to other compounds in its class. Furthermore, recent data suggest that figitumumab might be active in combination with platinum doublets for the treatment of chemotherapy-naive non-small-cell lung cancer (NSCLC). This article discusses the results to date of the figitumumab development program and the rationale for further testing of this agent as a therapeutic option for the treatment of patients with NSCLC.
AB - Figitumumab (CP-751,871) is a fully human immunoglobulin G2 monoclonal antibody highly potent and specific against the insulin-like growth factor-1 receptor. Figitumumab has an effective half-life of approximately 20 days, and it has been well tolerated in clinical studies when given alone or in combination with chemotherapy and targeted agents. Mild to moderate asymptomatic hyperglycemia is observed with figitumumab therapy, but it is generally manageable and well tolerated. Because of its extended half-life and absence of dose-limiting toxicity and hypersensitivity, figitumumab compares well to other compounds in its class. Furthermore, recent data suggest that figitumumab might be active in combination with platinum doublets for the treatment of chemotherapy-naive non-small-cell lung cancer (NSCLC). This article discusses the results to date of the figitumumab development program and the rationale for further testing of this agent as a therapeutic option for the treatment of patients with NSCLC.
KW - CP-751,871
KW - Insulin-like growth factor binding proteins
KW - Proof-of-concept trials
KW - Squamous histology
UR - http://www.scopus.com/inward/record.url?scp=70349443573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349443573&partnerID=8YFLogxK
U2 - 10.3816/CLC.2009.n.038
DO - 10.3816/CLC.2009.n.038
M3 - Review article
C2 - 19632947
AN - SCOPUS:70349443573
SN - 1525-7304
VL - 10
SP - 273
EP - 280
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 4
ER -